

Bradley T Andresen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4286352/bradley-t-andresen-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

186
citations

7
h-index

13
g-index

33
ext. papers

236
ext. citations

3
avg, IF

2.73
L-index

#	Paper	IF	Citations
31	Polymorphisms in common antihypertensive targets: Pharmacogenomic implications for the treatment of cardiovascular disease. <i>Advances in Pharmacology</i> , 2022 , 141-182	5.7	
30	Topical carvedilol delivery prevents UV-induced skin cancer with negligible systemic absorption. <i>International Journal of Pharmaceutics</i> , 2021 , 611, 121302	6.5	1
29	Prevention of Skin Carcinogenesis by the Non-Blocking R-carvedilol Enantiomer. <i>Cancer Prevention Research</i> , 2021 , 14, 527-540	3.2	3
28	The β -Blocker Carvedilol Prevented Ultraviolet-Mediated Damage of Murine Epidermal Cells and 3D Human Reconstructed Skin. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
27	In silico prediction of ARB resistance: A first step in creating personalized ARB therapy. <i>PLoS Computational Biology</i> , 2020 , 16, e1007719	5	2
26	Kinetic control of signaling: role of RGS proteins and GRKs. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
25	Topical Delivery of Carvedilol Loaded Nano-Transfersomes for Skin Cancer Chemoprevention. <i>Pharmaceutics</i> , 2020 , 12,	6.4	14
24	In silico prediction of ARB resistance: A first step in creating personalized ARB therapy 2020 , 16, e1007719		
23	In silico prediction of ARB resistance: A first step in creating personalized ARB therapy 2020 , 16, e1007719		
22	In silico prediction of ARB resistance: A first step in creating personalized ARB therapy 2020 , 16, e1007719		
21	In silico prediction of ARB resistance: A first step in creating personalized ARB therapy 2020 , 16, e1007719		
20	Carvedilol inhibits EGF-mediated JB6 P+ colony formation through a mechanism independent of adrenoceptors. <i>PLoS ONE</i> , 2019 , 14, e0217038	3.7	7
19	Structural determination of the mechanism of domain separation of G-protein-coupled receptor kinase 4g. <i>FASEB Journal</i> , 2019 , 33, 668.7	0.9	
18	Kinetic changes in G α cycling can increase cAMP accumulation while decreasing G protein-coupled receptor kinase-mediated receptor desensitization. <i>FASEB Journal</i> , 2019 , 33, 502.7	0.9	
17	Phosphoproteome profiling provides insight into the mechanism of action for carvedilol-mediated cancer prevention. <i>Molecular Carcinogenesis</i> , 2018 , 57, 997-1007	5	8
16	Modeling Angiotensin II-mediated activation of the Angiotensin II Type 1 Receptor. <i>FASEB Journal</i> , 2018 , 32, 555.16	0.9	
15	Impact of β adrenergic receptors on UV-induced skin damage, inflammation and photoprotective effect of carvedilol. <i>FASEB Journal</i> , 2018 , 32, 696.7	0.9	

14	A142V GRK4 increased RH-kinase domain separation is dependent on interaction with the plasma membrane. <i>FASEB Journal</i> , 2018 , 32, 687.4	0.9	
13	Valsartan 2017 ,		
12	Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis. <i>Cancer Prevention Research</i> , 2017 , 10, 598-606	3.2	14
11	The basis of translational physiology: from molecules to humans, a wide arc of scientific inquiry. <i>Physiology</i> , 2015 , 30, 4-5	9.8	
10	Prevention of skin carcinogenesis by the β -blocker carvedilol. <i>Cancer Prevention Research</i> , 2015 , 8, 27-36	3.2	23
9	DMH1, a small molecule inhibitor of BMP type I receptors, suppresses growth and invasion of lung cancer. <i>PLoS ONE</i> , 2014 , 9, e90748	3.7	31
8	Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket. <i>American Journal of Physiology - Renal Physiology</i> , 2013 , 304, F1105-13	4.3	5
7	The β -blocker Nebivolol Is a GRK/ β -arrestin biased agonist. <i>PLoS ONE</i> , 2013 , 8, e71980	3.7	50
6	Mapping the Binding of G Protein-Coupled Receptor Kinases 4 (GRK4) with G β . <i>FASEB Journal</i> , 2013 , 27, 1172.1	0.9	
5	Role of MEK and RSK in Blood Pressure Regulation. <i>FASEB Journal</i> , 2013 , 27, 708.5	0.9	
4	Proteomic assessment of the binding partners of GRK4—an approach to understand the molecular mechanisms of GRK4 action. <i>FASEB Journal</i> , 2013 , 27, 1172.10	0.9	
3	A pharmacological primer of biased agonism. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2011 , 11, 92-8	2.2	18
2	Characterization of G protein-coupled receptor kinase 4 and measuring its constitutive activity in vivo. <i>Methods in Enzymology</i> , 2010 , 484, 631-51	1.7	6
1	Rosuvastatin Attenuates Pulmonary Arterial Hypertension in the Transgenic (mREN2) ²⁷ (Ren2) Rat. <i>FASEB Journal</i> , 2009 , 23, 770.4	0.9	